Guideline-Concordant Antipsychotic Use and Mortality in Schizophrenia
Bernadette Cullen,Emma E. McGinty,Yiyi Zhang,Susan dosReis,Donald M. Steinwachs,Eliseo Guallar,Gail L. Daumit +6 more
Reads0
Chats0
TLDR
Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia and adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence should be considered.Abstract:
Objective: To determine if care concordant with 2009 Schizophrenia Patient Outcomes Research Team (PORT) pharmacological recommendations for schizophrenia is associated with decreased mortality. Methods: We conducted a retrospective cohort study of adult Maryland Medicaid beneficiaries with schizophrenia and any antipsychotic use from 1994 to 2004 (N = 2132). We used Medicaid pharmacy data to measure annual and average antipsychotic continuity, to calculate chlorpromazine (CPZ) dosing equivalents, and to examine anti-Parkinson medication use. Cox proportional hazards regression models were used to examine the relationship between antipsychotic continuity, antipsychotic dosing, and anti-Parkinson medication use and mortality. Results: Annual antipsychotic continuity was associated with decreased mortality. Among patients with annual continuity greater than or equal to 90%, the hazard ratio [HR] for mortality was 0.75 (95% confidence interval [CI] 0.57–0.99) compared with patients with annual medication possession ratios (MPRs) of less than 10%. The HRs for mortality associated with continuous annual and average antipsychotic continuity were 0.75 (95% CI 0.58–0.98) and 0.84 (95% CI 0.58–1.21), respectively. Among users of first-generation antipsychotics, doses greater than or equal to 1500 CPZ dosing equivalents were associated with increased risk of mortality (HR 1.88, 95% CI 1.10–3.21), and use of anti-Parkinson medication was associated with decreased risk of mortality (HR 0.72, 95% CI 0.55–0.95). Mental health visits were also associated with decreased mortality (HR 0.96, 95% CI 0.93–0.98). Conclusions: Adherence to PORT pharmacological guidelines is associated with reduced mortality among patients with schizophrenia. Adoption of outcomes monitoring systems and innovative service delivery programs to improve adherence to the PORT guidelines should be considered.read more
Citations
More filters
Journal ArticleDOI
Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas
Nancy H. Liu,Nancy H. Liu,Gail L. Daumit,Tarun Dua,Ralph Aquila,Fiona J Charlson,Pim Cuijpers,Benjamin G. Druss,Kenn Dudek,Melvyn Freeman,Chiyo Fujii,Wolfgang Gaebel,Ulrich Hegerl,Itzhak Levav,Thomas Munk Laursen,Hong Ma,Mario Maj,María Elena Medina-Mora,Merete Nordentoft,Dorairaj Prabhakaran,Karen Pratt,Martin Prince,Thara Rangaswamy,David Shiers,Ezra Susser,Graham Thornicroft,Kristian Wahlbeck,Abe Fekadu Wassie,Harvey Whiteford,Shekhar Saxena +29 more
TL;DR: A comprehensive framework that may be useful for designing, implementing and evaluating interventions and programmes to reduce excess mortality in persons with SMD is described, incorporating lessons learned from the multilevel model of risk and the comprehensive intervention framework.
Journal ArticleDOI
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
Christoph U. Correll,Delbert Robinson,Nina R. Schooler,Nina R. Schooler,Mary F. Brunette,Kim T. Mueser,Robert A. Rosenheck,Patricia Marcy,Patricia Marcy,Jean Addington,Sue E. Estroff,James Robinson,David L. Penn,Susan T. Azrin,Amy B. Goldstein,Joanne B. Severe,Robert K. Heinssen,John M. Kane +17 more
TL;DR: In patients with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other.
Journal ArticleDOI
Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
Jari Tiihonen,Ellenor Mittendorfer-Rutz,Minna Torniainen,Kristina Alexanderson,Antti Tanskanen +4 more
TL;DR: Moderate and high-dose antipsychotic and antidepressant use were associated with 15%-40% lower overall mortality, whereas chronic high- dose use of benzodiazepines was associated with up to a 70% higher risk of death compared with no exposure.
Journal ArticleDOI
Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010
TL;DR: Numbers of excess deaths and attributable deaths clearly demonstrate the high degree of mortality associated with these disorders and the life expectancy gap between persons with MNSDs and the general population is high and should be a focus for health systems reform.
Journal ArticleDOI
The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders
Richard D. Hayes,Johnny Downs,Chin-Kuo Chang,Richard J. Jackson,Hitesh Shetty,Matthew Broadbent,Matthew Hotopf,Robert Stewart +7 more
TL;DR: A strong association between being prescribed clozapine and lower mortality was identified which persisted after controlling for a broad range of potential confounders including clinical monitoring and markers of disease severity and after restricting the sample to those with a diagnosis of schizophrenia or those taking antipsychotics.
References
More filters
Journal ArticleDOI
Comorbidity measures for use with administrative data.
TL;DR: The present method addresses some of the limitations of previous measures and produces an expanded set of comorbidities that easily is applied without further refinement to administrative data for a wide range of diseases.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Practice guideline for the treatment of patients with schizophrenia
Marvin I. Herz,Robert Paul Liberman,T. H. McGlashan,Jeffrey A. Lieberman,Richard Jed Wyatt,Stephen R. Marder,P. Wang,C. Allgulander,Ross J. Baldessarini,R. Balon,A. S. Bellack,C M Jr Berlin,C. H. Blackington,Peter F. Buckley,D. G. Carlson,J. Cott,Francine Cournos,P. Desai,L. Dickstein,Wayne Fenton,W. A. Fisher,Lois T. Flaherty,R. Freedman,Marc Galanter,E. Galton,Rohan Ganguli,L. K. Garrettson,S. Goldfinger,L. S. Goldman,M. Z. Goldstein,T. R. Gordy,S. H. Gray,Monica R. Green,W. M. Greenberg,John G. Gunderson,L. L. Hall,E. Haller,E. Hanin,L. Hawkins,T. W. Hester,T. Horn,J. K. Hsiao,N. V. Juthani,John M. Kane,A. Kayser,H. D. Kibel,R. A. Kimmich,R. R. Koegler,J. Krajeski,T. Kuehnel,J.S. Lamberti,Anthony F. Lehman,J. Leunello,R. L. Martin,R. McCarley,Mark McGee,Herbert Y. Meltzer,M.-Marsel Mesulam,Jeffrey L. Metzner,Loren R. Mosher,J. A. Motto,Kim T. Mueser,R. A. Munoz,H. A. Nasrallah,J. W. Newcomer,Lewis A. Opler,G. N. Peterson,M. Rapaport,Michelle Riba,V. I. Rickert,A. Rifkin,J. S. Rivenbark,S. Robertson,P. Ruiz,W. G. Ryan,M. O. Sanderson,R. B. Schiffer,P. M. Schyve,R. H. Sebring,W. W. Shen,D. Shore,G. M. Simpson,H. E. Soufi,L. I. Stein,N. Stotland,J. Strauss,D. Sundberg,D. Svendsen,Mauricio Tohen,M. Tsuang,J. G. Wagnitz,Richard D. Weiner,W. D. Weitzel,L. J. Wilkerson,D. Wingerson,C A Jr Zarate,J. Zito,Howard Zonana +97 more
Journal ArticleDOI
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?
TL;DR: In light of the potential for second-generation antipsychotic medications to further adversely influence mortality rates in the decades to come, optimizing the general health of people with schizophrenia warrants urgent attention.